Immunic (IMUX) Accumulated Expenses (2013 - 2026)

Immunic has disclosed Accumulated Expenses across 14 years of filings, most recently posting $22.4 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $22.4 million, up 22.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.4 million (up 22.65% YoY), and the FY2025 annual result was $18.6 million, up 44.39% from the prior year.
• Accumulated Expenses came in at $22.4 million for Q1 2026 at Immunic, up from $18.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $22.4 million in Q1 2026 to a low of $5.7 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $13.7 million (2023), against an average of $13.8 million.
• Across the five-year window, Accumulated Expenses soared 133.71% in 2023 and slumped 30.81% in 2024, its largest moves.
• Immunic's Accumulated Expenses stood at $8.0 million in 2022, then soared by 133.71% to $18.7 million in 2023, then plunged by 30.81% to $12.9 million in 2024, then jumped by 44.39% to $18.6 million in 2025, then advanced by 20.31% to $22.4 million in 2026.
• The last three Accumulated Expenses figures came in at $22.4 million (Q1 2026), $18.6 million (Q4 2025), and $19.5 million (Q3 2025), per Business Quant data.